加载中
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
前收盘价
US$9.05
+US$0.0617 · +0.69%
盘前
US$7.80
−US$1.25 · -13.81%
10月13日 6:24 ET
盘中时间采用ET。市场数据可能有所延迟。
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
日内区间
当前US$9.05
52周区间
当前US$9.05
盘中时间采用ET。市场数据可能有所延迟。
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
日内区间
当前US$9.05
52周区间
当前US$9.05
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 34.2万 USD | 11.8万 USD | 4000 USD | 5000 USD | 6000 USD |
| 毛利 | −34.2万 USD | −11.8万 USD | −4000 USD | −5000 USD | −6000 USD |
| 研究与开发 | 213.3万 USD | 53.4万 USD | 33.2万 USD | 34.7万 USD | 24.5万 USD |
| 销售、一般及管理费用 | 377.4万 USD | 76.8万 USD | 30.3万 USD | 54.8万 USD | 45.2万 USD |
| 营业费用 | 590.7万 USD | 130.2万 USD | 63.5万 USD | 89.5万 USD | 69.7万 USD |
| 利息收入 | 37万 USD | — | — | — | — |
| 利息支出 | 314.3万 USD | 3000 USD | 2000 USD | 2000 USD | 2000 USD |
| 折旧和摊销 | 34.2万 USD | 11.8万 USD | 4000 USD | 5000 USD | 6000 USD |
| 营业利润 | −624.9万 USD | −130.2万 USD | −63.5万 USD | −89.5万 USD | −70.3万 USD |
| 净利润 | −333.5万 USD | −154.5万 USD | −60万 USD | −77.9万 USD | −71.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年11月28日 | 1:6 | — | — |
股票拆分 | 2025年5月27日 | 1:250 | — | — |
已生效 2025年11月28日
1:6
已生效 2025年5月27日
1:250
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
